instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: "The story covers cost in the very last two lines. Adequate quantification of benefits seen in the study. Story says ""few eye-related complications"" were reported in the Lucentis group, but didn't say what few means or what they were. We don't think that's quite adequate. Adequate job explaining how the study was done and what it means. No disease mongering in the story. One quote from the head of the National Eye Institute. But he didn't really evaluate evidence only talked about hope. Meantime, no mention that Genentech funded the trial (a strength of the NYT story was its discussion of the ""pay for play"" aspect of the research) and no mention that Dr. Bressler disclosed financial ties to Genentech. From the Times: Some doctors criticized the organizers of the trial for testing Lucentis rather than another Genentech drug, Avastin, which works in the same way as Lucentis. Although it is a cancer drug, Avastin is often used off-label for eye diseases because it is far cheaper than Lucentis, costing only $20 to $100 a dose, compared with $2,000 for Lucentis. Avastin is undercutting sales of Lucentis, which totaled $1.1 billion in the United States last year. Organizers of the trial conceded that a major reason Lucentis was chosen was that Genentech, which is now owned by Roche, agreed to provide the drug free of charge and to contribute $9 million in additional financing but only if Lucentis were used. "Obviously you can't underplay $9 million," said Dr. Ferris of the eye institute, which is part of the part of the National Institutes of Health. But he said there were other factors as well, like a belief that Lucentis might have been the better drug. Dr. Philip J. Rosenfeld, a professor of ophthalmology at the University of Miami, said the decision was "clearly a case of pay to play" since Genentech's money dictated the choice of drugs. At least the story mentioned the uncertainty about whether Lucentis is any better than the cheaper Avastin, and mentioned an upcoming trial comparing the two in age-related macular degeneration. The story explains that Lucentis was approved 4 years ago for another cause. Story explains the drug is already approved for another use, and it also at the very end mentions that an older and much cheaper drug is also effective. It's clear the story did not rely on a news release." Claim: Drug Reverses Diabetes-Related Vision Loss
answer:
The key difference between this and the NYT story was that WebMD didn't reflect on the question of why Genentech didn't test its cheaper Avastin against the much more expensive Lucentis. The important issue of corporate sponsorship of a clinical trial was overlooked. You want to talk about comparative effectiveness research? This would have been a good place for it.

question:
Paragraph: Moncef Slaoui, a former GlaxoSmithKline executive, will lead "Operation Warp Speed," Trump's push to accelerate the vaccine development process for COVID-19, according to an administration official. Slaoui is to serve in a volunteer capacity, and will be assisted by Army Gen. Gustave Perna, the commander of United States Army Materiel Command. The move comes as the president and White House aides hope to produce vaccines for the coronavirus faster than what many scientists believe is realistic. The administration is aiming to have 300 million doses to distribute to Americans by the end of the year, believing a reliable vaccine is the only way to promote an economic rebound. "Operation Warp Speed" is operating largely independently of the existing White House coronavirus task force, which is also shifting its focus toward vaccine development. The initiative is being promoted by White House senior adviser Jared Kushner, and involves officials from the Defense Department and the Department of Health and Human Services. On Tuesday, Dr. Anthony Fauci, the government's top infectious disease expert, said a vaccine would not be available by the beginning of the next academic year. "The idea of having treatments available or a vaccine to facilitate re-entry of students into the fall term would be something that would be a bit of a bridge too far," he said, "even at the top speed we're going." Claim: Trump to name former pharma exec as vaccine czar.
answer:
President Donald Trump is set to name a former pharmaceutical executive to lead his administration's all-out effort to produce and distribute a coronavirus vaccine by the end of the year.

question:
Paragraph: They said reducing stress during breast cancer treatment can keep the immune system strong and improve a woman's quality of life and these two factors help women live longer. They found women who took part in a support group where they were taught to cope with their stress through relaxation techniques and problem solving lived an average of six months longer than other women. "If you have someone who can provide effective, research-supported ways to reduce your stress, not only will that affect your mental health. It will likely affect your symptoms and your recovery," said Barbara Andersen, a psychology professor at Ohio State University in Columbus. The study is rare because while it makes sense that therapy might ease some of the stress of cancer treatment, few studies have shown it can boost a woman's survival. The findings appear in the journal Cancer Clinical Research. The study included 227 women with newly diagnosed Stage II or III breast cancer. Women in the study got either a psychological assessment or therapy that helped them understand their stress, learn ways to cope with it, stay on their cancer treatment, improve communication with their doctor and generally feel better emotionally during their treatment and recovery. "It was far more than the popular notion of support groups of patients in a room talking about their troubles," Andersen said in a telephone interview. "Certain patients talked about things that were stressful to them, but they also learned really effective ways to cope with that stress." For example, women were taught relaxation techniques that helped lower stress levels. They were counseled on how to assess the individual strengths of people in their support network knowing which people can be counted on for emotional support and which would be most reliable if the woman needed a ride to therapy. The support group met weekly for four months, than monthly for a total of a year. In prior findings from the study, the team found that women who had taken part in the support group had stronger immune systems and were 45 percent less likely to have their breast cancer come back after 11 years of follow up. The latest phase of the study looked at the group of women whose cancer did return. Of these 62 women, those who had gotten talk therapy were 59 percent less likely to die from their breast cancer during the study period. The survival benefit was above and beyond improvements in drug treatments. Andersen said these results "show enduring benefits" from the support group that had never before been considered or seen. "An intervention that increased survival would be incredibly valuable. It represents a new tool for improving the lives of women with breast cancer," Sarah Gehlert of Washington University in St. Louis, who was not involved in the study, said in a statement. Andersen said most women with breast cancer would not be able to take part in such a support group at the moment, but she hopes the findings will encourage insurance companies to pay for them, and for hospitals to begin offering such services. Claim: Learning to relax, cope extends cancer survival.
answer:
Working with a psychologist to reduce stress can help women whose breast cancer comes back survive longer, U.S. researchers said on Tuesday.